134 related articles for article (PubMed ID: 35753987)
1. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study.
Carr SB; McClenaghan E; Elbert A; Faro A; Cosgriff R; Abdrakhmanov O; Brownlee K; Burgel PR; Byrnes CA; Cheng SY; Colombo C; Corvol H; Daneau G; Goss CH; Gulmans V; Gutierrez H; Harutyunyan S; Helmick M; Jung A; Kashirskaya N; McKone E; Melo J; Middleton PG; Mondejar-Lopez P; de Monestrol I; Nährlich L; Padoan R; Parker M; Pastor-Vivero MD; Rizvi S; Ruseckaite R; Salvatore M; da Silva-Filho LVRF; Versmessen N; Zampoli M; Marshall BC; Stephenson AL;
J Cyst Fibros; 2022 Jul; 21(4):e221-e231. PubMed ID: 35753987
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.
Bain R; Cosgriff R; Zampoli M; Elbert A; Burgel PR; Carr SB; Castaños C; Colombo C; Corvol H; Faro A; Goss CH; Gutierrez H; Jung A; Kashirskaya N; Marshall BC; Melo J; Mondejar-Lopez P; de Monestrol I; Naehrlich L; Padoan R; Pastor-Vivero MD; Rizvi S; Salvatore M; Filho LVRFDS; Brownlee KG; Haq IJ; Brodlie M
J Cyst Fibros; 2021 Jan; 20(1):25-30. PubMed ID: 33309057
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.
Tedbury PR; Manfredi C; Degenhardt F; Conway J; Horwath MC; McCracken C; Sorscher AJ; Moreau S; Wright C; Edwards C; Brewer J; Guarner J; de Wit E; Williamson BN; Suthar MS; Ong YT; Roback JD; Alter DN; Holter JC; Karlsen TH; Sacchi N; Romero-Gómez M; Invernizzi P; Fernández J; Buti M; Albillos A; Julià A; Valenti L; Asselta R; Banales JM; Bujanda L; de Cid R; Franke A; ; Sarafianos SG; Hong JS; Sorscher EJ; Ehrhardt A
FASEB J; 2023 Nov; 37(11):e23220. PubMed ID: 37801035
[TBL] [Abstract][Full Text] [Related]
4. Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society.
Colombo C; Cipolli M; Daccò V; Medino P; Alghisi F; Ambroni M; Badolato R; Battistini F; Bignamini E; Casciaro R; Ciciriello F; Collura M; Comello I; Francalanci M; Ficili F; Folino A; Leonardi S; Leonetti G; Lucanto MC; Lucca F; Maschio M; Mencarini V; Messore B; Pisi G; Pizzamiglio G; Poli P; Raia V; Riberi L; Ros M; Rotolo N; Sepe A; Taccetti G; Vitullo P; Alicandro G
Infection; 2022 Jun; 50(3):671-679. PubMed ID: 34874541
[TBL] [Abstract][Full Text] [Related]
5. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.
McClenaghan E; Cosgriff R; Brownlee K; Ahern S; Burgel PR; Byrnes CA; Colombo C; Corvol H; Cheng SY; Daneau G; Elbert A; Faro A; Goss CH; Gulmans V; Gutierrez H; de Monestrol I; Jung A; Justus LN; Kashirskaya N; Marshall BC; McKone E; Middleton PG; Mondejar-Lopez P; Pastor-Vivero MD; Padoan R; Rizvi S; Ruseckaite R; Salvatore M; Stephenson AL; Filho LVRDS; Melo J; Zampoli M; Carr SB;
J Cyst Fibros; 2020 Nov; 19(6):868-871. PubMed ID: 33183965
[TBL] [Abstract][Full Text] [Related]
6. TGF-β1 Inhibition of ACE2 Mediated by miRNA Uncovers Novel Mechanism of SARS-CoV-2 Pathogenesis.
Hejenkowska ED; Mitash N; Donovan JE; Chandra A; Bertrand C; De Santi C; Greene CM; Mu F; Swiatecka-Urban A
J Innate Immun; 2023; 15(1):629-646. PubMed ID: 37579743
[TBL] [Abstract][Full Text] [Related]
7. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.
Naehrlich L; Orenti A; Dunlevy F; Kasmi I; Harutyunyan S; Pfleger A; Keegan S; Daneau G; Petrova G; Tješić-Drinković D; Yiallouros P; Bilkova A; Olesen HV; Burgel PR; Parulava T; Diamantea F; Párniczky A; McKone EF; Mei-Zahav M; Salvatore M; Colombo C; Aleksejeva E; Malakauskas K; Schlesser M; Fustik S; Turcu O; Zomer-van Ommen D; Wathne AS; Woźniacki Ł; Pereira L; Pop L; Kashirskaya N; Rodić M; Kayserova H; Krivecs U; Mondejar-Lopez P; de Monestrol I; Dogru D; Makukh H; Cosgriff R; van Koningsbruggen-Rietschel S; Jung A;
J Cyst Fibros; 2021 Jul; 20(4):566-577. PubMed ID: 34016559
[TBL] [Abstract][Full Text] [Related]
8. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
9. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.
Jung A; Orenti A; Dunlevy F; Aleksejeva E; Bakkeheim E; Bobrovnichy V; Carr SB; Colombo C; Corvol H; Cosgriff R; Daneau G; Dogru D; Drevinek P; Vukic AD; Fajac I; Fox A; Fustik S; Gulmans V; Harutyunyan S; Hatziagorou E; Kasmi I; Kayserová H; Kondratyeva E; Krivec U; Makukh H; Malakauskas K; McKone EF; Mei-Zahav M; de Monestrol I; Olesen HV; Padoan R; Parulava T; Pastor-Vivero MD; Pereira L; Petrova G; Pfleger A; Pop L; van Rens JG; Rodic M; Schlesser M; Storms V; Turcu O; Woz Niacki L; Yiallouros P; Zolin A; Downey DG; Naehrlich L
ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34984210
[TBL] [Abstract][Full Text] [Related]
10. Ethnic variation in outcome of people hospitalised during the first COVID-19 epidemic wave in Wales (UK): an analysis of national surveillance data using Onomap, a name-based ethnicity classification tool.
Thomas DR; Orife O; Plimmer A; Williams C; Karani G; Evans MR; Longley P; Janiec J; Saltus R; Shankar AG
BMJ Open; 2021 Aug; 11(8):e048335. PubMed ID: 34408047
[TBL] [Abstract][Full Text] [Related]
11. The impact of SARS-CoV-2 infection in patients with cystic fibrosis undergoing CFTR channel modulators treatment: a literature review.
Vitiello A; Sabbatucci M; Silenzi A; Capuano A; Rossi F; Zovi A; Blasi F; Rezza G
Respir Res; 2023 Nov; 24(1):278. PubMed ID: 37957647
[TBL] [Abstract][Full Text] [Related]
12. Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey.
Mondejar-Lopez P; Quintana-Gallego E; Giron-Moreno RM; Cortell-Aznar I; Ruiz de Valbuena-Maiz M; Diab-Caceres L; Prados-Sanchez C; Alvarez-Fernandez A; Garcia-Marcos PW; Peñalver-Mellado C; Pastor-Vivero MD; Olveira C; Lopez-Neyra A; Castillo-Corullon S; Palma-Milla S; Perez-Ruiz E; Sole-Jover A; Barrio MI; Sanchez-Solis M; Asensio de la Cruz Ó;
Respir Med; 2020; 170():106062. PubMed ID: 32843180
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir for the treatment of COVID-19.
Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis.
Hergenroeder GE; Faino AV; Cogen JD; Genatossio A; McNamara S; Pascual M; Hernandez RE
Pediatr Pulmonol; 2023 Sep; 58(9):2478-2486. PubMed ID: 37314149
[TBL] [Abstract][Full Text] [Related]
15. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.
Webb GJ; Marjot T; Cook JA; Aloman C; Armstrong MJ; Brenner EJ; Catana MA; Cargill T; Dhanasekaran R; García-Juárez I; Hagström H; Kennedy JM; Marshall A; Masson S; Mercer CJ; Perumalswami PV; Ruiz I; Thaker S; Ufere NN; Barnes E; Barritt AS; Moon AM
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):1008-1016. PubMed ID: 32866433
[TBL] [Abstract][Full Text] [Related]
16. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.
Sawicki GS; Van Brunt K; Booth J; Bailey E; Millar SJ; Konstan MW; Flume PA
J Cyst Fibros; 2022 Jan; 21(1):96-103. PubMed ID: 34289939
[TBL] [Abstract][Full Text] [Related]
17. A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.
Cosgriff R; Ahern S; Bell SC; Brownlee K; Burgel PR; Byrnes C; Corvol H; Cheng SY; Elbert A; Faro A; Goss CH; Gulmans V; Marshall BC; McKone E; Middleton PG; Ruseckaite R; Stephenson AL; Carr SB;
J Cyst Fibros; 2020 May; 19(3):355-358. PubMed ID: 32376098
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis.
Marques LS; Boschiero MN; Sansone NMS; Brienze LR; Marson FAL
Healthcare (Basel); 2023 Jul; 11(13):. PubMed ID: 37444770
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and outcomes of incident cases of COVID-19 in unvaccinated adult cystic fibrosis patients in southern Brazil: a prospective cohort study conducted during the first year of the COVID-19 pandemic.
Camargo CC; Jacobsen LB; Wilsmann J; Silveira MN; Ziegler B; Rossi EP; Oliveira CT; Dalcin PTR
J Bras Pneumol; 2022; 48(6):e20220265. PubMed ID: 36449821
[TBL] [Abstract][Full Text] [Related]
20. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
Ramsey ML; Gokun Y; Sobotka LA; Wellner MR; Porter K; Kirkby SE; Li SS; Papachristou GI; Krishna SG; Stanich PP; Hart PA; Conwell DL; Lara LF
Am J Gastroenterol; 2021 Dec; 116(12):2446-2454. PubMed ID: 34665155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
